Max S. Mano

TL;DR: Among patients with HER2‐positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T‐DM1 than with trastuzumab alone.

TL;DR: Treatment with adjuvant trastuzumab for 1 year after chemotherapy is associated with significant clinical benefit at 4-year median follow-up and a substantial selective crossover of patients in the observation group to trastzumab was associated with improved outcomes for this cohort.

TL;DR: In this article, the authors present the findings of their Cancer Commission and their recommendations to encourage Latin American stakeholders to redouble their efforts to address this increasing cancer burden and to prevent it from worsening and threatening their societies.

TL;DR: In this largest clinical trial of β-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction.

TL;DR: The BOLERO-1 study assessed the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer and in the subset of patients with hormone receptor-negative breast cancer at baseline.